Welcome to our dedicated page for OrthoPediatrics news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on OrthoPediatrics stock.
OrthoPediatrics Corp. (symbol: KIDS) is a global leader in pediatric orthopedics, exclusively focusing on providing innovative solutions for children with orthopedic conditions and injuries. The company is dedicated to advancing pediatric orthopedics by developing state-of-the-art technologies, ensuring high-quality products, and offering unparalleled support and clinical education through its team of experts.
OrthoPediatrics offers a wide range of anatomically appropriate implants and instruments designed to meet the unique needs of pediatric orthopedic surgeons. Their product portfolio includes solutions for long bone deformity correction and trauma, spine, and sports medicine. Among their flagship products are PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and the ACL Reconstruction System.
Recent achievements of OrthoPediatrics include issuing the 2024 financial guidance and recording a full-year revenue of $148.7 million in 2023, marking a 22% increase compared to the previous year. As of December 31, 2023, the company had cash and cash equivalents, short-term investments, and restricted cash totaling $82.3 million. The recent acquisition of Boston Orthotics & Prosthetics was a significant milestone, further reinforcing their market position.
In the first quarter of 2024, OrthoPediatrics reported a 41% increase in revenue year-over-year. The company's total other expense was $0.6 million for the quarter, primarily due to a favorable fair value adjustment in the previous year that did not recur in 2024, as well as additional interest expenses related to a new term loan with MidCap. As of March 31, 2024, the company's cash, cash equivalents, short-term investments, and restricted cash were $49.7 million.
OrthoPediatrics continues to seek talented professionals to join their mission. Interested candidates can visit their website to learn about current openings or submit their resumes to careers@orthopediatrics.com. For the latest updates, news, and developments, shareholders and potential investors can find the most recent information on OrthoPediatrics Corp. through this page.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its Diamond sponsorship for the 31st Annual Baltimore Limb Deformity Course, returning to a live format after a virtual event in 2020. The event will take place from August 4 to 8 in Baltimore, Maryland, where the company will offer registration scholarships to residents and fellows. OrthoPediatrics will also showcase its External Fixation portfolio through hands-on demonstrations and workshops. Newly appointed CEO David Bailey emphasized the event's significance in pediatric orthopedic education.
OrthoPediatrics Corp. (NASDAQ: KIDS) is set to announce its second quarter 2021 financial results on August 5, 2021, prior to market opening. A conference call will follow at 8:00 a.m. ET, providing insights into the financial performance. Interested parties can join via dial-in numbers or online webcast. OrthoPediatrics, established in 2006, focuses exclusively on pediatric orthopedics, offering 36 surgical systems across major categories such as trauma, scoliosis, and sports medicine. The company distributes globally, affecting pediatric orthopedic care.
OrthoPediatrics Corp. (NASDAQ: KIDS) has launched its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis (SCFE) Cannulated Screw system after receiving FDA 510(k) clearance. This innovative system features fully and partially threaded screws designed specifically for pediatric patients, available in 2mm increments. The addition expands OrthoPediatrics' offerings, which now includes screws in multiple sizes to meet the needs of pediatric orthopedic surgeons. This launch reinforces the company's commitment to advancing pediatric orthopedic care.
OrthoPediatrics Corp (Nasdaq: KIDS) announced participation in the 2021 JMP Securities Life Sciences Conference on June 17, 2021. Key executives, including CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl, will engage in a fireside chat at 12:00pm ET. An audio webcast of the event will be available on the company's investor relations website, with a replay accessible for 90 days post-event. OrthoPediatrics specializes in pediatric orthopedics, offering 36 surgical systems across trauma, scoliosis, and sports medicine.
OrthoPediatrics Corp. (Nasdaq: KIDS) has completed a leadership transition, appointing David Bailey as the new Chief Executive Officer, succeeding Mark Throdahl, who will remain as Executive Chairman. Throdahl praised Bailey's experience since joining the company in 2007, expressing confidence in his leadership. Bailey emphasized that the company's strategy will remain unchanged, focusing on executing growth plans and delivering innovative products for pediatric orthopedic surgeons to improve children's lives. The company markets 36 surgical systems across key categories in pediatric orthopedics.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched its RESPONSE™ Neuromuscular Scoliosis System, marking its 36th surgical system introduction. The system, cleared by the FDA in 2020, targets pediatric patients with neuromuscular scoliosis, developed in collaboration with pediatric orthopedic surgeons. This innovative system integrates with existing RESPONSE Scoliosis offerings and aims to enhance surgical efficiency and patient outcomes. OrthoPediatrics focuses exclusively on pediatric orthopedic solutions, distributing in the U.S. and 45 other countries.
OrthoPediatrics Corp. (NASDAQ: KIDS) has reaffirmed its support for the 2021 Pediatric Orthopaedic Society of North America (POSNA) annual meeting, which saw over 400 participants despite COVID-19 challenges. As a Double Diamond Sponsor, the company contributed to educational symposia and scholarships. The press release highlighted its Scoliosis franchise, particularly the ApiFix technology, designed for less invasive scoliosis correction. With 48 patents and a focus on pediatric orthopedics, OrthoPediatrics is dedicated to enhancing treatment options for children.
OrthoPediatrics Corp. (KIDS) reported a 31.2% year-over-year revenue increase for Q1 2021, totaling $21.5 million. Domestic revenue grew by 25.8%, while international revenue surged 55.6%. The company achieved notable revenue gains across various segments: Trauma & Deformity revenue rose 19.2%, Scoliosis by 60.4%, and Sports Medicine/Other by 120.5%. Despite an operating loss of ($6.0 million) and a net loss of ($10.4 million), OrthoPediatrics maintains a strong balance sheet with $78.0 million in cash. The company has raised its 2021 revenue guidance to a range of $94-98 million.
OrthoPediatrics Corp. (Nasdaq: KIDS) will participate in a fireside chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021. The session will feature company executives including President Dave Bailey, COO and CFO Fred Hite, and CEO Mark Throdahl. The fireside chat will provide insights into the advancement of pediatric orthopedics, showcasing OrthoPediatrics' commitment to improving children's lives through innovative surgical systems. The event will be available via a webcast at 1:00 PM ET, with a replay available for 90 days.
OrthoPediatrics Corp. (NASDAQ: KIDS) will release its Q1 2021 financial results on May 5, 2021, after the market closes. A conference call to discuss these results is scheduled for May 6, 2021, at 8:00 a.m. ET, with dial-in numbers for domestic and international participants. The company focuses exclusively on pediatric orthopedics, offering a broad range of surgical systems across trauma, scoliosis, and sports medicine. Its products are distributed in the U.S. and 44 other countries.
FAQ
What is the current stock price of OrthoPediatrics (KIDS)?
What is the market cap of OrthoPediatrics (KIDS)?
What does OrthoPediatrics Corp. do?
What are some of OrthoPediatrics' key products?
What were OrthoPediatrics' financial highlights for 2023?
How did OrthoPediatrics perform in the first quarter of 2024?
What recent acquisition did OrthoPediatrics make?
How much cash and equivalents did OrthoPediatrics have as of March 31, 2024?
What is OrthoPediatrics' focus in pediatric orthopedics?
Where can I learn about career opportunities at OrthoPediatrics?
Who can I contact for investor relations at OrthoPediatrics?
What recent financial guidance did OrthoPediatrics issue?
